SCHEMBL17559372

SCHEMBL17559372

COC(=O)c1ccc(C(=O)N2CCN(C(=O)O)CC2)cc1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HPGD P15428 4/20 0.61
GPR183 P32249 1/20 0.56
ALDH1A1 P00352 4/20 0.52
KMT2A Q03164 1/20 0.52
TSHR P16473 1/20 0.50
ALOX15 P16050 1/20 0.50
MGLL Q99685 1/20 0.50
HSD17B10 Q99714 1/20 0.50
LMNA P02545 1/20 0.49
POLB P06746 1/20 0.49
TDP1 Q9NUW8 1/20 0.48
CA12 O43570 1/20 0.48
CA1 P00915 1/20 0.48
CA2 P00918 1/20 0.48
CA7 P43166 1/20 0.48
CA9 Q16790 1/20 0.48
CA14 Q9ULX7 1/20 0.48
EPHX1 P07099 1/20 0.48
EPHX2 P34913 1/20 0.48
CRBN Q96SW2 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8658563 0.93 HPGD (0.68) HPGDGPR183ALDH1A1KMT2ATSHR
SCHEMBL17559469 0.86 HPGD (0.61) HPGDGPR183ALDH1A1KMT2AALOX15
SCHEMBL17559346 0.86 HPGD (0.61) HPGDGPR183ALDH1A1KMT2AALOX15
SCHEMBL64495 0.86 HPGD (0.78) HPGDGPR183ALDH1A1KMT2ATSHR
SCHEMBL70433 0.86 HPGD (0.69) HPGDGPR183ALDH1A1KMT2A
SCHEMBL4620335 0.86 HPGD (0.73) HPGDGPR183ALDH1A1KMT2AALOX15
SCHEMBL23675251 0.84 HPGD (0.71) HPGDALDH1A1KMT2ATSHR
SCHEMBL3025580 0.83 ALDH1A1 (0.63) HPGDALDH1A1KMT2ATSHRALOX15
SCHEMBL23280363 0.83 HPGD (0.58) HPGDGPR183ALDH1A1KMT2AALOX15
SCHEMBL25110067 0.82 HPGD (0.57) HPGDGPR183ALDH1A1KMT2ATSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230062119-A1 USE OF BIOMARKERS IN IDENTIFYING PATIENTS THAT WILL BE RESPONSIVE TO TREATMENT WITH A PRMT5 INHIBITOR MERCK SHARP & DOHME LLC (US) 2023-03-02 US disclosed
US-11390610-B2 Piperazine derivatives as MAGL inhibitors HOFFMANN-LA ROCHE INC. (US) 2022-07-19 US disclosed
EP-3694840-B1 PIPERAZINE DERIVATIVES AS MAGL INHIBITORS HOFFMANN LA ROCHE (CH) 2021-08-04 EP disclosed
WO-2021126999-A1 USE OF BIOMARKERS IN IDENTIFYING PATIENTS THAT WILL BE RESPONSIVE TO TREATMENT WITH A PRMT5 INHIBITOR MERCK SHARP & DOHME CORP. (US) 2021-06-24 WO disclosed
EP-3189041-B1 TETRAHYDROISOQUINOLINE DERIVED PRMT5-INHIBITORS CTXT PTY LTD (AU) 2021-04-28 EP disclosed
US-20200299277-A1 PIPERAZINE DERIVATIVES AS MAGL INHIBITORS HOFFMANN-LA ROCHE INC. (US) 2020-09-24 US disclosed
US-20170298075-A1 TETRAHYDROISOQUINOLINE DERIVED PRMT5-INHIBITORS CTXT PTY. LTD. (AU) 2017-10-19 US disclosed
EP-3189041-A1 TETRAHYDROISOQUINOLINE DERIVED PRMT5-INHIBITORS Ctxt Pty Ltd (AU) 2017-07-12 EP disclosed
WO-2016034673-A1 TETRAHYDROISOQUINOLINE DERIVED PRMT5-INHIBITORS CTXT PTY LTD (AU) 2016-03-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170298075-A1 TETRAHYDROISOQUINOLINE DERIVED PRMT5-INHIBITORS PRMT5, PRMT1, PRMT3 HPGD 2195/4885GPR183 3376/4885ALDH1A1 4190/4885
US-11390610-B2 Piperazine derivatives as MAGL inhibitors MAGI3, PYM1, MAG HPGD 4094/4885GPR183 1954/4885ALDH1A1 3240/4885
US-20200299277-A1 PIPERAZINE DERIVATIVES AS MAGL INHIBITORS MAGI3, PYM1, MAG HPGD 4094/4885GPR183 1954/4885ALDH1A1 3240/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.